{"url_path":"/sec/rnac/8-k/2026-06-09/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-09","source_url":"https://www.sec.gov/Archives/edgar/data/1453687/0001140361-26-024556-index.html","accession_number":"0001140361-26-024556","cik":"0001453687","ticker":"RNAC","issuer_name":"Cartesian Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1453687/0001140361-26-024556-index.html","primary_entity_key":"0001453687","primary_entity_name":"Cartesian Therapeutics, Inc."},"word_count":168,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn June 9, 2026, Cartesian Therapeutics, Inc. (the “Company”) issued a press release announcing its entry into a strategic licensing\nagreement with WestGene Biopharma Co. (“WestGene”) to advance the development of novel in vivo chimeric antigen receptor T-cell (“CAR-T”) therapies in autoimmune diseases. A copy of the press release is attached as Exhibit 99.1 to this Current\nReport on Form 8-K.\n\nThe information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of\nSection 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as\namended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1, except as required by law."}